Literature DB >> 21288851

Impact of antiretroviral therapy on HIV-related brain injury.

Richard W Price.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21288851      PMCID： PMC3060892          DOI： 10.1093/cid/ciq052

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  26 in total

1.  HIV-associated neurocognitive disorders: is there a hidden epidemic?

Authors:  Justin C McArthur; Bruce J Brew
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

2.  Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.

Authors:  Sahra Abdulle; Lars Hagberg; Bo Svennerholm; Dietmar Fuchs; Magnus Gisslén
Journal:  AIDS       Date:  2002-11-08       Impact factor: 4.177

3.  The AIDS dementia complex: I. Clinical features.

Authors:  B A Navia; B D Jordan; R W Price
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

4.  Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.

Authors:  E J Wright; B Grund; K Robertson; B J Brew; M Roediger; M P Bain; F Drummond; M J Vjecha; J Hoy; C Miller; A C Penalva de Oliveira; W Pumpradit; J C Shlay; W El-Sadr; R W Price
Journal:  Neurology       Date:  2010-08-11       Impact factor: 9.910

5.  The prevalence and incidence of neurocognitive impairment in the HAART era.

Authors:  Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

6.  Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.

Authors:  Arvid Edén; Richard W Price; Serena Spudich; Dietmar Fuchs; Lars Hagberg; Magnus Gisslén
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

7.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

8.  Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Authors:  Ana Canestri; François-Xavier Lescure; Stephane Jaureguiberry; Antoine Moulignier; Corinne Amiel; Anne Geneviève Marcelin; Gilles Peytavin; Roland Tubiana; Gilles Pialoux; Christine Katlama
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

9.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

10.  Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.

Authors:  Krishnan Bhaskaran; Cristina Mussini; Andrea Antinori; Ann Sarah Walker; Maria Dorrucci; Caroline Sabin; Andrew Phillips; Kholoud Porter
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.